Prolonged hepatitis C virus seroconversion in a blood donor, detected by HCV Antigen test in parallel with HCV RNA
Prolonged hepatitis C virus seroconversion in a blood donor, detected by HCV Antigen test in parallel with HCV RNA
复制标题
通过 HCV 抗原检测与 HCV RNA 并行检测，献血者体内丙型肝炎病毒血清转化时间延长
DOI：
10.1111/j.0042-9007.2004.00513.x
复制
发表时间：
2004
期刊：
影响因子：
2.7
通讯作者：
E. Franco
中科院分区：
文献类型：
--
作者：
M. Álvarez;D. Planelles;E. Vila;J. Montoro;E. Franco
一些工业化国家正在以相当大的成本对献血进行丙型肝炎病毒（HCV）RNA筛查，以降低HCV传播的风险。当制造商为每单位测试的血液引入专利成本时，这种成本将变得不成比例地高[1]。自1999年7月以来，巴伦西亚社区输血中心（西班牙）的所有同种异体献血都通过逆转录聚合酶链反应（RT-PCR）（Ampliscreen HCV 2.0; Roche Diagnostics，Branchburg，NJ）对44或22份献血的小样本池进行了检测。
Some industrialized countries are screening blood donations for hepatitis C virus (HCV) RNA, at a considerable cost, in order to reduce the risk of HCV transmission. This cost will become disproportionately high when a patent cost is introduced by the manufacturers for each unit of blood tested [1]. Since July 1999, all allogeneic blood donations in the Valencian Community Blood Transfusion Centre (Spain) have been tested by reverse transcription–polymerase chain reaction (RT–PCR) (Ampliscreen HCV 2·0; Roche Diagnostics, Branchburg, NJ) analysis of minipools of 44 or 22 donations.